Third Rock Ventures
Executivos
Veja o organograma con seus 35 executivos principais
Biografias mais buscadas da Third Rock Ventures
- Chris Robinson, Chief Talent Officer
- Abbie Celniker, Partner, Formation, Development and Strategy
- Neil Exter, Partner, Formation, Development and Strategy
Recentes movimentos de executivos em Third Rock Ventures
- Courtney Wallace, ingressou na Companhia como Venture Partner (Notícia publicada em 26 de janeiro de 2024).
- Jigar Raythatha antes Venture Partner, foi promovido a Partner (Notícia publicada em 26 de janeiro de 2024).
- Vyas Ramanan antes Principal, foi promovido a Venture Partner (Notícia publicada em 26 de janeiro de 2024).
Clique aqui para ver outras movimentos em Third Rock Ventures
Criar um alerta
para seguir os movimentos de executivos da Third Rock Ventures.
Fundo
Third Rock Ventures possui 1.474 concorrentes concorrentes Lloyds Development Capital (Reino Unido), BlackRock (Estados Unidos) e WindRose Health Investors (Estados Unidos).
Popular M&A news in Fundo
- Abrdn Private Equity Opportunities Trust mudará seu nome para Patria Capital Partners. (publicado em 30 de abril de 2024).
- HMC Capital adquiriu StratCap (publicado em 28 de fevereiro de 2024).
- Thomvest Ventures acaba de anunciar uma arrecadação de fundos de 250 milhões de dólares. (publicado em 17 de janeiro de 2024).
Outros contatos sugeridos na indústria do Fundo
- Antonio Gracias - Founder, Chief Executive Officer and Chief Investment Officer da Valor Equity Partners
- Mortimer Buckley - Chairman of the Board and Chief Executive Officer (retiring in Dec 2024) da Vanguard
- Jean-Marc Arbaud - President and Chief Executive Officer of CDPQ Infra da Caisse de Dépôt et Placement du Québec
Notícias
Últimos comunicados de imprensa de Third Rock Ventures
- Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 | Tango Therapeutics, Inc
- Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis | Pliant Therapeutics, Inc.
- Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors - Septerna
- Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis | Pliant Therapeutics, Inc.
- CARGO Therapeutics Announces Pricing of Initial Public Offering | CARGO Therapeutics, Inc.
- Terremoto Biosciences Closes $175 Million Series B Financing | Terremoto
- Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
- Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023 | Pliant Therapeutics, Inc.
- Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer | Pliant Therapeutics, Inc.
- Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) | Fulcrum Therapeutics
- View more press releases Close
Redes sociais sobre Third Rock Ventures
- Third Rock Ventures na Wikipedia, Google News e Yahoo Finance
- Third Rock Ventures na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Alison Connors 
Ligue para a Third Rock Ventures em +1 617...
